Securities code: Cabio Biotech (Wuhan) Co.Ltd(688089) securities abbreviation: Cabio Biotech (Wuhan) Co.Ltd(688089) Announcement No.: 2022018
Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. board of directors, supervisors and senior management personnel centralized bidding to reduce shares for more than half of the time and announcement on the progress of reduction
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
Basic information about the shareholding of Dong Jiangao
Before the implementation of the reduction plan, Mr. Wang Huabiao, director and chief financial officer of Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. (hereinafter referred to as “the company”), held 1026817 shares of the company, accounting for 0.856% of the total share capital of the company; Mr. Du bin, director and vice chairman, holds 868845 shares of the company, accounting for 0.724% of the total share capital of the company; Mr. Wang Zhiming, deputy general manager of the company, holds 236958 shares of the company, accounting for 0.197% of the total share capital of the company; Mr. Li Xiangyu, deputy general manager of the company, holds 118479 shares of the company, accounting for 0.099% of the total share capital of the company; Mr. Ma Tao, deputy general manager of the company, holds 110581 shares of the company, accounting for 0.092% of the total share capital of the company; Geng Anfeng, deputy general manager of the company, holds 116900 shares of the company, accounting for 0.097% of the total share capital of the company; Mr. Yi Huarong, deputy general manager and Secretary of the board of directors of the company, holds 90834 shares of the company, accounting for 0.076% of the total share capital of the company; Mr. Wu Yujun, the supervisor of the company, holds 15797 shares of the company, accounting for 0.013% of the total share capital of the company. The above shares are the shares obtained before the company’s initial public offering and listing, and these shares have been listed and circulated since December 21, 2020.
Progress of centralized bidding reduction plan
On December 17, 2021, the company disclosed the announcement of the board of directors, supervisors and senior management of Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. on the plan of reducing shares through centralized bidding (Announcement No. 2021051). Mr. Wang Huabiao plans to reduce his shares in the company through centralized bidding, with a total number of no more than 229000 shares, accounting for no more than 0.191% of the company’s shares; Mr. Du bin plans to reduce his shares in the company through centralized bidding, with a total number of no more than 190000 shares, accounting for no more than 0.158% of the shares of the company; Mr. Wang Zhiming plans to reduce his shares in the company through centralized bidding, with a total number of no more than 50000 shares, accounting for 50% of the company’s shares
The proportion of shares shall not exceed 0.042%; Mr. Li Xiangyu plans to reduce his shares of the company through centralized bidding
The total number of shares shall not exceed 27000, accounting for no more than 0.023% of the shares of the company; Mr. Ma Tao’s plan
Reduce the shares of the company held by them through centralized bidding, with a total number of no more than 27645 shares, accounting for
The proportion of shares shall not exceed 0.023%; Mr. Geng Anfeng plans to reduce his holdings of the company through centralized bidding
The total number of shares shall not exceed 29225, accounting for no more than 0.024% of the shares of the company; Mr. Yi Huarong
It is planned to reduce its shares in the company through centralized bidding, with a total number of no more than 22000 shares, accounting for
The share proportion of the company shall not exceed 0.018%; Mr. Wu Yujun plans to reduce his holdings through centralized bidding
The total number of shares of the company shall not exceed 3949, accounting for no more than 0.0033% of the shares of the company. Reduction period
The period is from January 10, 2022 to July 9, 2022. If the holdings are reduced through centralized bidding trading, the
The total number of shares reduced within any consecutive 90 days shall not exceed 1% of the total share capital of the company. In case of legal problems during the reduction period
During the window period specified in the regulations, the reduction of shares shall be stopped. If the company has dividends, shares and capital reserve during the reduction period
The number of shares reduced will be adjusted accordingly for ex rights and ex dividend matters such as conversion of share capital and allotment of shares.
As of the disclosure date of this announcement, the planned time of this reduction has been more than half. The progress of the above reduction of directors, supervisors and senior managers is as follows:
Below:
Mr. Wang Huabiao has reduced 85 shares of the company, accounting for 0.0001% of the company’s shares; Wang Zhi
Mr. Ming has reduced 10000 shares of the company, accounting for 0.0083% of the company’s shares; Mr Geng Anfeng
11000 shares of the company have been reduced in total, accounting for 0.0092% of the shares of the company;
Mr. Wu Yujun has reduced 3949 shares of the company and has completed his reduction plan. See details of the company’s reduction plan
Centralized competition for supervisors of Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. disclosed on January 20, 2022
Announcement on the result of share reduction (Announcement No.: 2022006); Mr. Ma Tao has reduced 15000 shares of the company
The number of shares has been reduced by more than half. See Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. disclosed by the company on January 21, 2022 for details
Announcement on more than half of the reduction of shares and the progress of reduction of shares by some senior managers of Han (China) Co., Ltd. (public notice)
Report No.: 2022007);
In addition to the above reduction, other directors and senior managers in the reduction plan during this period
There has been no reduction of holdings.
1、 Basic information of the subject of centralized bidding reduction before reduction
Number of shares held
Shareholder name shareholder identity shareholding proportion current shareholding source (share)
Wang Huabiao’s directors, supervisors and senior management 10268170.856% acquired before IPO: 1026817 shares
Du Bin’s directors, supervisors and senior managers obtained 868845 shares 0.724% before IPO
Wang Zhiming’s directors, supervisors and senior managers obtained 236958 shares 0.197% before IPO
Director, supervisor and senior management of Li Xiangyu: 1184790.099% obtained before IPO: 118479 shares
Ma Tao’s directors, supervisors and senior managers obtained 110581 shares 0.092% before IPO
Geng Anfeng’s directors, supervisors and senior managers obtained 116900097% before IPO: 116900 shares
Directors, supervisors and senior managers of Yi Huarong obtained 90834 shares 0.076% before IPO
Wu Yujun’s directors, supervisors and senior managers obtained 15797 shares before 0.013% IPO
The above reduction subjects have no concerted action.
2、 Implementation progress of centralized bidding reduction plan
(I) the directors, supervisors and senior management disclosed the implementation progress of the centralized bidding reduction plan for the following reasons:
The reduction time is more than half
Number of shareholders’ holdings reduction price reduction total amount of holdings reduction current shareholding current name weight (share) proportion reduction mode range during the period of holdings reduction (yuan / (yuan) quantity (share) share proportion share)
Wang Huabiao 85 0.0001% 2022 / 1 / 10 ~ centralized bidding transaction 68.0657851010267320.856% 2022 / 4 / 10 -68.06
Du bin 0% 2022 / 1 / 10 ~ centralized bidding transaction 0-08688450.724% 2022 / 4 / 10
Wang Zhiming 100000.008% 2022 / 1 / 10 ~ centralized bidding transaction 67.76677600 Shanghai Metersbonwe Fashion&Accessories Co.Ltd(002269) 580.189% 2022 / 4 / 10 -67.76
Li Xiangyu 0 0% 2022 / 1 / 10 ~ centralized bidding transaction 0-0 01184790.099% 2022 / 4 / 10
Geng Anfeng 110000.009% 2022 / 1 / 10 ~ centralized bidding transaction 69.00760250001059000.088% 2022 / 4 / 10 – 69.15
Yi Huarong 0% 2022 / 1 / 10 ~ centralized bidding transaction 0-0908340.076% 2022 / 4 / 10
Note: Mr. Wu Yujun has completed his share reduction plan. See the details disclosed by the company on January 20, 2022
Announcement on the results of share reduction by centralized bidding of supervisors of Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. (company)
Report No.: 2022006); Mr. Ma Tao has more than half of the planned reduction. For details, please refer to the announcement on the reduction of more than half of the planned reduction by centralized bidding of some senior managers of Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. (Announcement No.: 2022007) disclosed by the company on January 21, 2022. (II) whether the reduction is consistent with the plans and commitments previously disclosed by the major shareholders or the directors, supervisors and senior management √ yes □ no (III) whether the listed company discloses major matters such as high transfer or planning merger and reorganization within the reduction time interval □ yes √ no (IV) the impact of the reduction on the company
This reduction plan is carried out by the company’s shareholders, directors and senior managers according to their own needs. The implementation subject is not the controlling shareholder of the company, which will not lead to the change of the company’s controlling right and will not have a significant impact on the company’s governance structure and sustainable operation. (V) other matters required by the exchange
None. 3、 Risk tips related to the centralized bidding reduction plan (I) uncertainty risk of the implementation of the reduction plan, such as the preconditions and restrictive conditions for the implementation of the plan, as well as the specific conditions for the achievement or elimination of relevant conditions, etc
The reduction plan is the reduction of the company’s shareholders according to their own needs. During the reduction period, the shareholders will decide whether to continue to implement and how to implement the reduction plan according to market conditions, the company’s share price and other factors. There are uncertainties such as the reduction time, reduction quantity and reduction price. (II) whether the implementation of the share reduction plan will lead to the risk of change in the control of the listed company □ yes √ no (III) other risks
As of the disclosure date of this announcement, the implementation of this reduction plan has not been completed. The company will continue to pay attention to the progress of the implementation of the shareholders’ share reduction plan, and timely fulfill the obligation of information disclosure in accordance with the provisions of relevant laws and regulations. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Cabio Biotech (Wuhan) Co.Ltd(688089) Biotechnology (Wuhan) Co., Ltd. board of directors April 11, 2022
